Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04559009 · ClinicalTrials.gov registry record
COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 47
- Enrollment target
NCT04559009: Completed study, sponsored by Wake Forest University Health Sciences.
NCT04559009 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04559009 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 47 participants
- Enrollment target
Study Summary
Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal neurodegenerative disease characterized by progressive weakness involving limb, bulbar, and respiratory muscles.There is currently no information suggesting how COVID-19 affects patients diagnosed with amyotrophic lateral sclerosis (ALS). This is especially important as respiratory compromise is common in ALS patients and can complicate the clinical course as COVID-19 could lead to respiratory failure and need for intubation. We intend that this registry will guide our understanding of how COVID-19 affects patients with ALS.
Primary Outcome
Assessed through outcomes reporting ranging from recovered infections to patient death reported in a patient facing registry.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2023-01-31 |
What the finished NCT04559009 record still lists
NCT04559009 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 47 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04559009 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04559009 about?
NCT04559009 is a clinical study titled "COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry". Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal neurodegenerative disease characterized by progressive weakness involving limb, bulbar, and respiratory muscles.There is currently no information suggesting how COVID-19 affects patients diagnosed with amyotrophic lateral sc...
What is the current status of trial NCT04559009?
This trial is currently completed. The enrollment target is 47 participants. The study started on 2020-10-15. Estimated completion is 2023-01-31.
Who is sponsoring clinical trial NCT04559009?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI